Most Popular
1. Banking Crisis is Stocks Bull Market Buying Opportunity - Nadeem_Walayat
2.The Crypto Signal for the Precious Metals Market - P_Radomski_CFA
3. One Possible Outcome to a New World Order - Raymond_Matison
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
5. Apple AAPL Stock Trend and Earnings Analysis - Nadeem_Walayat
6.AI, Stocks, and Gold Stocks – Connected After All - P_Radomski_CFA
7.Stock Market CHEAT SHEET - - Nadeem_Walayat
8.US Debt Ceiling Crisis Smoke and Mirrors Circus - Nadeem_Walayat
9.Silver Price May Explode - Avi_Gilburt
10.More US Banks Could Collapse -- A Lot More- EWI
Last 7 days
Stock Market Volatility (VIX) - 25th Mar 24
Stock Market Investor Sentiment - 25th Mar 24
The Federal Reserve Didn't Do Anything But It Had Plenty to Say - 25th Mar 24
Stock Market Breadth - 24th Mar 24
Stock Market Margin Debt Indicator - 24th Mar 24
It’s Easy to Scream Stocks Bubble! - 24th Mar 24
Stocks: What to Make of All This Insider Selling- 24th Mar 24
Money Supply Continues To Fall, Economy Worsens – Investors Don’t Care - 24th Mar 24
Get an Edge in the Crypto Market with Order Flow - 24th Mar 24
US Presidential Election Cycle and Recessions - 18th Mar 24
US Recession Already Happened in 2022! - 18th Mar 24
AI can now remember everything you say - 18th Mar 24
Bitcoin Crypto Mania 2024 - MicroStrategy MSTR Blow off Top! - 14th Mar 24
Bitcoin Gravy Train Trend Forecast 2024 - 11th Mar 24
Gold and the Long-Term Inflation Cycle - 11th Mar 24
Fed’s Next Intertest Rate Move might not align with popular consensus - 11th Mar 24
Two Reasons The Fed Manipulates Interest Rates - 11th Mar 24
US Dollar Trend 2024 - 9th Mar 2024
The Bond Trade and Interest Rates - 9th Mar 2024
Investors Don’t Believe the Gold Rally, Still Prefer General Stocks - 9th Mar 2024
Paper Gold Vs. Real Gold: It's Important to Know the Difference - 9th Mar 2024
Stocks: What This "Record Extreme" Indicator May Be Signaling - 9th Mar 2024
My 3 Favorite Trade Setups - Elliott Wave Course - 9th Mar 2024
Bitcoin Crypto Bubble Mania! - 4th Mar 2024
US Interest Rates - When WIll the Fed Pivot - 1st Mar 2024
S&P Stock Market Real Earnings Yield - 29th Feb 2024
US Unemployment is a Fake Statistic - 29th Feb 2024
U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - 29th Feb 2024
What a Breakdown in Silver Mining Stocks! What an Opportunity! - 29th Feb 2024
Why AI will Soon become SA - Synthetic Intelligence - The Machine Learning Megatrend - 29th Feb 2024
Keep Calm and Carry on Buying Quantum AI Tech Stocks - 19th Feb 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

A Clear Way to Profit from a Graying Population

Companies / Healthcare Sector Jul 21, 2014 - 03:25 PM GMT

By: Money_Morning

Companies

Ernie Tremblay writes: The Baby Boom generation, which includes everyone born from 1946 through 1964, is now entering retirement age (65) at a rate of 10,000 per day. That demographic wave is so big that in 2010, the U.S. Administration on Aging (AoA) predicted the elderly population in this country would double to about 71 million by 2030.

That presents a huge opportunity for bioscience investors. Here's why.


As people grow older, as a group, they get sicker. About 80% of older adults cope with at least one chronic condition - illnesses that need to be managed but can't be cured - and 50% struggle with two or more. Here are some of them:

  • Alzheimer's and other dementias
  • Arthritis
  • Balance and gait problems
  • Bladder conditions
  • Cardiovascular disease
  • Cerebrovascular disease
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Depression
  • Diabetes
  • Eye disease (glaucoma, cataracts, macular degeneration)
  • High blood pressure
  • Kidney disease
  • Osteoporosis
  • Parkinson's disease
  • Prostatic hyperplasia (enlarged prostate)

Infectious diseases such as pneumonia, and injuries such as hip fractures from falling, also take a big toll on our older adults.

Naturally, the more seniors there are, the more demand there will be on the medical community for better and safer therapies to manage their health.

It's Already Happening

But that isn't the whole story. Not only are there more elders now than ever before, but they're living longer. According to the Centers for Disease Control and Prevention, life expectancy currently stands at 78.7 years for adults in the United States. Compare that to a century ago, when the average figure was 47.3 years, or a half-century ago, in 1964, when it was 70.3 years.

Thanks to advances in medicine and improved public sanitation, we've made huge strides in longevity. But the outlook isn't as rosy as the numbers suggest, because living longer means more years of dealing with those chronic conditions mentioned above.

All of this costs a lot of money. In 2010, older adults represented only 13% of the population, but accounted for 34% of total healthcare dollars spent. That's $1.3 trillion. And that's a heck of a market.

So as investors, where does all of this take us?

Obviously, with all this demand for better treatment, drugs that help manage chronic conditions associated with age will be on everyone's watch list. And they're already paying off.

Let's take a look at just one of these diseases: adult onset (type 2) diabetes.

Since the beginning of the year, MannKind Corp.'s (Nasdaq: MNKD) price per share (PPS) has risen from $5.31 to $9.70 (as I write this), an increase of more than 80%.

During that time, MNKD's new drug in development, Afrezza, an inhalable form of insulin for type 2 diabetes, received a positive recommendation from a U.S. Food and Drug Administration (FDA) advisory committee (AdCom), and then, a couple of months later, FDA approval. Predictably, both of these catalysts helped drive up PPS.

Immediately after the AdCom, PPS soared more than 100% in a single trading session.

And I suspect Afrezza won't be the last diabetes drug to deliver high profits to investors.

Opportunities Abound

In the coming months, several more new drugs will try to improve the lot of patients with diabetes, including two at opposite ends of the price spectrum...

The first, Evoke Pharma Inc. (Nasdaq: EVOK), will release data from a phase 3 trial of its experimental drug EVK-001, a potential treatment for women with recurrent diabetic gastroparesis. The data follows successful results from a previous phase 2 study of the drug.

Gastroparesis, a common side effect of diabetes, causes the stomach to take too long to empty its contents. Among its symptoms are nausea, vomiting, abdominal pain, bloating, lack of appetite, and weight loss. Up to 4% of the American population - more than 13 million people - suffer with it. A disproportionate number of them are older adults. That's a very big potential market.

Currently, EVOK is a micro cap, with a market capitalization of $42 million and a PPS in the $7 range. This stock could be a remarkable bargain for investors, but trading volume is typically low - an average of about 18,000 shares per day over three months, and currently only around 7,000. Low volume can limit buying/selling opportunities - you can't sell a stock if you can't find a buyer. Short percentage of the float is only around 7%, so the market has some confidence in the company.

The second company, GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH), is a little pricier, with a PPS around $84 and a market cap of nearly $1.5 billion. Shares currently stand at about 950% of their value one year ago.

GWPH creates, develops, and commercializes substances derived from the marijuana plant to treat disease. One of its experimental products, GWP42004, has shown very positive clinical results in a phase 2a trial for the treatment of type 2 diabetes. The company is now doing a placebo-controlled, double-blind study of the drug in diabetic patients, which should be completed by the second half of next year. I would expect successful data to drive up stock value significantly, despite the currently high price tag.

Wealth is there for the finding...

As I say, diabetes is only one example of the many age-associated conditions that will demand more and more attention from the medical research and development community over the coming decade.

There are many more golden opportunities for the investor who is willing to do a little research and find creative bioscience firms developing therapies in these areas.

And remember, these opportunities aren't limited to therapeutics. Long-term care, nursing care, in-home care, and hospice are all areas that should prove attractive to investors.

It's all just a Web search away.

Source : http://moneymorning.com/2014/07/21/a-clear-way-to-profit-from-a-graying-population/

Money Morning/The Money Map Report

©2014 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in